Hemangiopericytoma in the central nervous system

Treatment, pathological features, and long-term follow up in 38 patients

Robert D. Ecker, W. Richard Marsh, Bruce E. Pollock, Özlem Kurtkaya-Yapicier, Robyn McClelland, Bernd W. Scheithauer, Jan Craig Buckner

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Object. The authors reviewed the Mayo Clinic experience with the treatment of hemangiopericytoma in the primary central nervous system (CNS). Methods. A retrospective study of all patients at the Mayo Clinic revealed 38 who had been treated for hemangiopericytoma in the CNS. Twenty of these patients were diagnosed in the decade between 1990 and 2000; 18 were initially diagnosed and underwent surgery before 1990. In the patients treated since 1990, the 5-year Kaplan-Meier survival rate was 93%. The 5-year disease-free survival rate was 89%. Sixty percent of patients treated with the aid of stereotactic radiosurgery for recurrent disease were alive 4.4 years after their initial treatment. Salvage chemotherapy was not effective. No survival benefit was detected in patients who had received initial adjuvant external-beam radiation therapy. High-grade tumors recurred 6.7 years earlier than did low-grade lesions (p = 0.004). Conclusions. The 5-year survival rate in patients with hemangiopericytoma of the CNS has improved at the authors' institution during the last 10 years. Although the reason for this is not entirely clear, the authors suspect that the improved treatment of patients with cancer, a 0% intraoperative mortality rate, and the use of radiosurgery in the treatment of recurrent disease all likely contribute. High-grade tumors recurred statistically significantly earlier than low-grade lesions. Current chemotherapies are ineffective in the treatment of hemangiopericytoma of the CNS.

Original languageEnglish (US)
Pages (from-to)1182-1187
Number of pages6
JournalJournal of Neurosurgery
Volume98
Issue number6
StatePublished - Jun 1 2003

Fingerprint

Hemangiopericytoma
Central Nervous System
Survival Rate
Radiosurgery
Therapeutics
Drug Therapy
Neoplasms
Disease-Free Survival
Radiotherapy
Retrospective Studies
Survival
Mortality

Keywords

  • Hemangiopericytoma
  • Radiosurgery
  • Radiotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Ecker, R. D., Marsh, W. R., Pollock, B. E., Kurtkaya-Yapicier, Ö., McClelland, R., Scheithauer, B. W., & Buckner, J. C. (2003). Hemangiopericytoma in the central nervous system: Treatment, pathological features, and long-term follow up in 38 patients. Journal of Neurosurgery, 98(6), 1182-1187.

Hemangiopericytoma in the central nervous system : Treatment, pathological features, and long-term follow up in 38 patients. / Ecker, Robert D.; Marsh, W. Richard; Pollock, Bruce E.; Kurtkaya-Yapicier, Özlem; McClelland, Robyn; Scheithauer, Bernd W.; Buckner, Jan Craig.

In: Journal of Neurosurgery, Vol. 98, No. 6, 01.06.2003, p. 1182-1187.

Research output: Contribution to journalArticle

Ecker, RD, Marsh, WR, Pollock, BE, Kurtkaya-Yapicier, Ö, McClelland, R, Scheithauer, BW & Buckner, JC 2003, 'Hemangiopericytoma in the central nervous system: Treatment, pathological features, and long-term follow up in 38 patients', Journal of Neurosurgery, vol. 98, no. 6, pp. 1182-1187.
Ecker RD, Marsh WR, Pollock BE, Kurtkaya-Yapicier Ö, McClelland R, Scheithauer BW et al. Hemangiopericytoma in the central nervous system: Treatment, pathological features, and long-term follow up in 38 patients. Journal of Neurosurgery. 2003 Jun 1;98(6):1182-1187.
Ecker, Robert D. ; Marsh, W. Richard ; Pollock, Bruce E. ; Kurtkaya-Yapicier, Özlem ; McClelland, Robyn ; Scheithauer, Bernd W. ; Buckner, Jan Craig. / Hemangiopericytoma in the central nervous system : Treatment, pathological features, and long-term follow up in 38 patients. In: Journal of Neurosurgery. 2003 ; Vol. 98, No. 6. pp. 1182-1187.
@article{cfb59af5776b4180a2f7eff4f16ff1db,
title = "Hemangiopericytoma in the central nervous system: Treatment, pathological features, and long-term follow up in 38 patients",
abstract = "Object. The authors reviewed the Mayo Clinic experience with the treatment of hemangiopericytoma in the primary central nervous system (CNS). Methods. A retrospective study of all patients at the Mayo Clinic revealed 38 who had been treated for hemangiopericytoma in the CNS. Twenty of these patients were diagnosed in the decade between 1990 and 2000; 18 were initially diagnosed and underwent surgery before 1990. In the patients treated since 1990, the 5-year Kaplan-Meier survival rate was 93{\%}. The 5-year disease-free survival rate was 89{\%}. Sixty percent of patients treated with the aid of stereotactic radiosurgery for recurrent disease were alive 4.4 years after their initial treatment. Salvage chemotherapy was not effective. No survival benefit was detected in patients who had received initial adjuvant external-beam radiation therapy. High-grade tumors recurred 6.7 years earlier than did low-grade lesions (p = 0.004). Conclusions. The 5-year survival rate in patients with hemangiopericytoma of the CNS has improved at the authors' institution during the last 10 years. Although the reason for this is not entirely clear, the authors suspect that the improved treatment of patients with cancer, a 0{\%} intraoperative mortality rate, and the use of radiosurgery in the treatment of recurrent disease all likely contribute. High-grade tumors recurred statistically significantly earlier than low-grade lesions. Current chemotherapies are ineffective in the treatment of hemangiopericytoma of the CNS.",
keywords = "Hemangiopericytoma, Radiosurgery, Radiotherapy",
author = "Ecker, {Robert D.} and Marsh, {W. Richard} and Pollock, {Bruce E.} and {\"O}zlem Kurtkaya-Yapicier and Robyn McClelland and Scheithauer, {Bernd W.} and Buckner, {Jan Craig}",
year = "2003",
month = "6",
day = "1",
language = "English (US)",
volume = "98",
pages = "1182--1187",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "6",

}

TY - JOUR

T1 - Hemangiopericytoma in the central nervous system

T2 - Treatment, pathological features, and long-term follow up in 38 patients

AU - Ecker, Robert D.

AU - Marsh, W. Richard

AU - Pollock, Bruce E.

AU - Kurtkaya-Yapicier, Özlem

AU - McClelland, Robyn

AU - Scheithauer, Bernd W.

AU - Buckner, Jan Craig

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Object. The authors reviewed the Mayo Clinic experience with the treatment of hemangiopericytoma in the primary central nervous system (CNS). Methods. A retrospective study of all patients at the Mayo Clinic revealed 38 who had been treated for hemangiopericytoma in the CNS. Twenty of these patients were diagnosed in the decade between 1990 and 2000; 18 were initially diagnosed and underwent surgery before 1990. In the patients treated since 1990, the 5-year Kaplan-Meier survival rate was 93%. The 5-year disease-free survival rate was 89%. Sixty percent of patients treated with the aid of stereotactic radiosurgery for recurrent disease were alive 4.4 years after their initial treatment. Salvage chemotherapy was not effective. No survival benefit was detected in patients who had received initial adjuvant external-beam radiation therapy. High-grade tumors recurred 6.7 years earlier than did low-grade lesions (p = 0.004). Conclusions. The 5-year survival rate in patients with hemangiopericytoma of the CNS has improved at the authors' institution during the last 10 years. Although the reason for this is not entirely clear, the authors suspect that the improved treatment of patients with cancer, a 0% intraoperative mortality rate, and the use of radiosurgery in the treatment of recurrent disease all likely contribute. High-grade tumors recurred statistically significantly earlier than low-grade lesions. Current chemotherapies are ineffective in the treatment of hemangiopericytoma of the CNS.

AB - Object. The authors reviewed the Mayo Clinic experience with the treatment of hemangiopericytoma in the primary central nervous system (CNS). Methods. A retrospective study of all patients at the Mayo Clinic revealed 38 who had been treated for hemangiopericytoma in the CNS. Twenty of these patients were diagnosed in the decade between 1990 and 2000; 18 were initially diagnosed and underwent surgery before 1990. In the patients treated since 1990, the 5-year Kaplan-Meier survival rate was 93%. The 5-year disease-free survival rate was 89%. Sixty percent of patients treated with the aid of stereotactic radiosurgery for recurrent disease were alive 4.4 years after their initial treatment. Salvage chemotherapy was not effective. No survival benefit was detected in patients who had received initial adjuvant external-beam radiation therapy. High-grade tumors recurred 6.7 years earlier than did low-grade lesions (p = 0.004). Conclusions. The 5-year survival rate in patients with hemangiopericytoma of the CNS has improved at the authors' institution during the last 10 years. Although the reason for this is not entirely clear, the authors suspect that the improved treatment of patients with cancer, a 0% intraoperative mortality rate, and the use of radiosurgery in the treatment of recurrent disease all likely contribute. High-grade tumors recurred statistically significantly earlier than low-grade lesions. Current chemotherapies are ineffective in the treatment of hemangiopericytoma of the CNS.

KW - Hemangiopericytoma

KW - Radiosurgery

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0038527166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038527166&partnerID=8YFLogxK

M3 - Article

VL - 98

SP - 1182

EP - 1187

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 6

ER -